TY  - JOUR
AU  - Obradović, Milan M.
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Ilinčić, Branislava
AU  - Stokić, Edita
AU  - Perović, Milan
AU  - Isenović, Esma R.
PY  - 2018
UR  - http://www.eurekaselect.com/158061/article
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7916
AB  - Despite the intensive research and progress in modern pharmacotherapy, hypercholesterolemia and related cardiovascular complications remain one of the leading causes of mortality and disability in the modern world. A significant contribution to the treatment of hypercholesterolemia was made by the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9). This enzyme is responsible for the degradation of the low-density lipoprotein (LDL) receptor (LDLR) found at the surface of the plasma membrane in the liver and directly associated with serum LDL level. Limitations in standard therapy used in the treatment of lipid disorders have led to the development of new drugs, such as an inhibitor of PCSK9. Over the past years, the greatest achievement in discovering the PCSK9 inhibitor was made by designing monoclonal antibodies that disable PCSK9 to bind LDLR and RNA interference to reduce PCSK9 production, but one of the main disadvantages is costeffectiveness. In this review, we will summarize the most recent findings of basic and clinical studies which focus on PCSK9 function, regulation and therapeutic target for the treatment of hypercholesterolemia and associated cardiovascular diseases.
T2  - Current Drug Targets
T1  - PCSK9 and Hypercholesterolemia: Therapeutic Approach
VL  - 19
IS  - 9
SP  - 1058
EP  - 1067
DO  - 10.2174/1389450119666171205101401
ER  - 

@article{
author = "Obradović, Milan M. and Zarić, Božidarka and Sudar-Milovanović, Emina and Ilinčić, Branislava and Stokić, Edita and Perović, Milan and Isenović, Esma R.",
year = "2018",
abstract = "Despite the intensive research and progress in modern pharmacotherapy, hypercholesterolemia and related cardiovascular complications remain one of the leading causes of mortality and disability in the modern world. A significant contribution to the treatment of hypercholesterolemia was made by the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9). This enzyme is responsible for the degradation of the low-density lipoprotein (LDL) receptor (LDLR) found at the surface of the plasma membrane in the liver and directly associated with serum LDL level. Limitations in standard therapy used in the treatment of lipid disorders have led to the development of new drugs, such as an inhibitor of PCSK9. Over the past years, the greatest achievement in discovering the PCSK9 inhibitor was made by designing monoclonal antibodies that disable PCSK9 to bind LDLR and RNA interference to reduce PCSK9 production, but one of the main disadvantages is costeffectiveness. In this review, we will summarize the most recent findings of basic and clinical studies which focus on PCSK9 function, regulation and therapeutic target for the treatment of hypercholesterolemia and associated cardiovascular diseases.",
journal = "Current Drug Targets",
title = "PCSK9 and Hypercholesterolemia: Therapeutic Approach",
volume = "19",
number = "9",
pages = "1058-1067",
doi = "10.2174/1389450119666171205101401"
}

Obradović, M. M., Zarić, B., Sudar-Milovanović, E., Ilinčić, B., Stokić, E., Perović, M.,& Isenović, E. R.. (2018). PCSK9 and Hypercholesterolemia: Therapeutic Approach. in Current Drug Targets, 19(9), 1058-1067.
https://doi.org/10.2174/1389450119666171205101401

Obradović MM, Zarić B, Sudar-Milovanović E, Ilinčić B, Stokić E, Perović M, Isenović ER. PCSK9 and Hypercholesterolemia: Therapeutic Approach. in Current Drug Targets. 2018;19(9):1058-1067.
doi:10.2174/1389450119666171205101401 .

Obradović, Milan M., Zarić, Božidarka, Sudar-Milovanović, Emina, Ilinčić, Branislava, Stokić, Edita, Perović, Milan, Isenović, Esma R., "PCSK9 and Hypercholesterolemia: Therapeutic Approach" in Current Drug Targets, 19, no. 9 (2018):1058-1067,
https://doi.org/10.2174/1389450119666171205101401 . .

TY  - JOUR
AU  - Stokić, Edita
AU  - Romani, Andrea
AU  - Ilinčić, Branislava
AU  - Kupusinac, Aleksandar
AU  - Stošić, Zoran
AU  - Isenović, Esma R.
PY  - 2018
UR  - http://www.eurekaselect.com/155079/article
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7951
AB  - Background: Obesity and micronutrient deficiencies contribute to the risk of cardiometabolic diseases such are type 2 diabetes mellitus and Cardiovascular Disease (CVD). Objective: We examined the frequency of concomitant deficit of Magnesium (Mg) and vitamin D in obese patients and evaluated the connection of these combined deficiencies with indicators of cardiometabolic risk in non-diabetic subjects. Methods: Non-diabetic middle aged adults (n = 80; mean age 36 +/- 4 years, 52% women) were recruited based on weight/adiposity parameters {[}i.e. Body Mass Index (BMI) and body fat percentage (FAT%)]. Cardiometabolic risk indicators {[}insulin resistance (Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)) and CVD risk (Framingham risk score for predicting 10-year CVD)], Mg status (i.e. total serum Mg concentration (TMg), Chronic Latent Mg Deficiency (CLMD) -0.75-0.85 mmol/L), vitamin D status (i.e. serum concentration of 25-hydroxyvitamin D (25(OH) D), vitamin D deficiency < 50 nmol/l) were assessed. Results: Among obese subjects 36% presented a combination of vitamin D deficiency and CLMD. In all studied patients, 25(OH) D and TMg levels both, individually and combined, showed a negative linear correlation with HOMA-IR and CVD risk. In subjects with CLMD (TMg < 0.85 mmol/L), a negative linear coefficient was found between 25(OH) D and, HOMA-IR and CVD risk, compared with subjects with normal TMg status (TMg >= 0.85 mmol/L). Conclusion: CLMD and vitamin D deficiency may commonly be present in obese non-diabetic subjects. Individually and combined, both deficiencies predispose non-diabetic patients to increased risk of cardiometabolic diseases. Maintaining normal Mg status may improve the beneficial effects of vitamin D on cardiometabolic risk indicators.
T2  - Current Vascular Pharmacology
T1  - Chronic Latent Magnesium Deficiency in Obesity Decreases Positive Effects of Vitamin D on Cardiometabolic Risk Indicators
VL  - 16
IS  - 6
SP  - 610
EP  - 617
DO  - 10.2174/1570161115666170821154841
ER  - 

@article{
author = "Stokić, Edita and Romani, Andrea and Ilinčić, Branislava and Kupusinac, Aleksandar and Stošić, Zoran and Isenović, Esma R.",
year = "2018",
abstract = "Background: Obesity and micronutrient deficiencies contribute to the risk of cardiometabolic diseases such are type 2 diabetes mellitus and Cardiovascular Disease (CVD). Objective: We examined the frequency of concomitant deficit of Magnesium (Mg) and vitamin D in obese patients and evaluated the connection of these combined deficiencies with indicators of cardiometabolic risk in non-diabetic subjects. Methods: Non-diabetic middle aged adults (n = 80; mean age 36 +/- 4 years, 52% women) were recruited based on weight/adiposity parameters {[}i.e. Body Mass Index (BMI) and body fat percentage (FAT%)]. Cardiometabolic risk indicators {[}insulin resistance (Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)) and CVD risk (Framingham risk score for predicting 10-year CVD)], Mg status (i.e. total serum Mg concentration (TMg), Chronic Latent Mg Deficiency (CLMD) -0.75-0.85 mmol/L), vitamin D status (i.e. serum concentration of 25-hydroxyvitamin D (25(OH) D), vitamin D deficiency < 50 nmol/l) were assessed. Results: Among obese subjects 36% presented a combination of vitamin D deficiency and CLMD. In all studied patients, 25(OH) D and TMg levels both, individually and combined, showed a negative linear correlation with HOMA-IR and CVD risk. In subjects with CLMD (TMg < 0.85 mmol/L), a negative linear coefficient was found between 25(OH) D and, HOMA-IR and CVD risk, compared with subjects with normal TMg status (TMg >= 0.85 mmol/L). Conclusion: CLMD and vitamin D deficiency may commonly be present in obese non-diabetic subjects. Individually and combined, both deficiencies predispose non-diabetic patients to increased risk of cardiometabolic diseases. Maintaining normal Mg status may improve the beneficial effects of vitamin D on cardiometabolic risk indicators.",
journal = "Current Vascular Pharmacology",
title = "Chronic Latent Magnesium Deficiency in Obesity Decreases Positive Effects of Vitamin D on Cardiometabolic Risk Indicators",
volume = "16",
number = "6",
pages = "610-617",
doi = "10.2174/1570161115666170821154841"
}

Stokić, E., Romani, A., Ilinčić, B., Kupusinac, A., Stošić, Z.,& Isenović, E. R.. (2018). Chronic Latent Magnesium Deficiency in Obesity Decreases Positive Effects of Vitamin D on Cardiometabolic Risk Indicators. in Current Vascular Pharmacology, 16(6), 610-617.
https://doi.org/10.2174/1570161115666170821154841

Stokić E, Romani A, Ilinčić B, Kupusinac A, Stošić Z, Isenović ER. Chronic Latent Magnesium Deficiency in Obesity Decreases Positive Effects of Vitamin D on Cardiometabolic Risk Indicators. in Current Vascular Pharmacology. 2018;16(6):610-617.
doi:10.2174/1570161115666170821154841 .

Stokić, Edita, Romani, Andrea, Ilinčić, Branislava, Kupusinac, Aleksandar, Stošić, Zoran, Isenović, Esma R., "Chronic Latent Magnesium Deficiency in Obesity Decreases Positive Effects of Vitamin D on Cardiometabolic Risk Indicators" in Current Vascular Pharmacology, 16, no. 6 (2018):610-617,
https://doi.org/10.2174/1570161115666170821154841 . .

TY  - JOUR
AU  - Stokić, Edita
AU  - Kupusinac, Aleksandar
AU  - Tomic-Naglic, Dragana
AU  - Smiljenic, Dragana
AU  - Kovacev-Zavisic, Branka
AU  - Srdić-Galić, Biljana
AU  - Soskić, Sanja S.
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1589
T2  - Angiology
T1  - Vitamin D and Dysfunctional Adipose Tissue in Obesity (Authors Reply)
VL  - 68
IS  - 6
SP  - 561
EP  - 561
DO  - 10.1177/0003319717691435
ER  - 

@article{
author = "Stokić, Edita and Kupusinac, Aleksandar and Tomic-Naglic, Dragana and Smiljenic, Dragana and Kovacev-Zavisic, Branka and Srdić-Galić, Biljana and Soskić, Sanja S. and Isenović, Esma R.",
year = "2017",
journal = "Angiology",
title = "Vitamin D and Dysfunctional Adipose Tissue in Obesity (Authors Reply)",
volume = "68",
number = "6",
pages = "561-561",
doi = "10.1177/0003319717691435"
}

Stokić, E., Kupusinac, A., Tomic-Naglic, D., Smiljenic, D., Kovacev-Zavisic, B., Srdić-Galić, B., Soskić, S. S.,& Isenović, E. R.. (2017). Vitamin D and Dysfunctional Adipose Tissue in Obesity (Authors Reply). in Angiology, 68(6), 561-561.
https://doi.org/10.1177/0003319717691435

Stokić E, Kupusinac A, Tomic-Naglic D, Smiljenic D, Kovacev-Zavisic B, Srdić-Galić B, Soskić SS, Isenović ER. Vitamin D and Dysfunctional Adipose Tissue in Obesity (Authors Reply). in Angiology. 2017;68(6):561-561.
doi:10.1177/0003319717691435 .

Stokić, Edita, Kupusinac, Aleksandar, Tomic-Naglic, Dragana, Smiljenic, Dragana, Kovacev-Zavisic, Branka, Srdić-Galić, Biljana, Soskić, Sanja S., Isenović, Esma R., "Vitamin D and Dysfunctional Adipose Tissue in Obesity (Authors Reply)" in Angiology, 68, no. 6 (2017):561-561,
https://doi.org/10.1177/0003319717691435 . .

TY  - JOUR
AU  - Ilinčić, Branislava
AU  - Stokić, Edita
AU  - Stošić, Zoran
AU  - Kojić, Nevena Eremic
AU  - Katsiki, Niki
AU  - Mikhailidis, Dimitri P.
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1371
AB  - Introduction: Obesity and inadequate vitamin D status are associated with endothelial dysfunction and cardiovascular disease. We evaluated the associations between vitamin D status (i.e. serum levels of 25-hydroxyvitamin D (25(OH)D)), biomarkers of endothelial dysfunction (i.e. serum concentrations of soluble intercellular adhesion molecule 1 (sICAM-1) and soluble E-selectin (sE-selectin)), inflammatory markers (i.e. high-sensitivity C-reactive protein (hsCRP) and fibrinogen) and cardiometabolic risk factors. Material and methods: Fifty obese (body mass index (BMI) GT = 30 kg/m(2)) non-diabetic adults (mean age: 36.2 +/- 5.4 years) without pre-existing cardiovascular abnormalities and 25 clinically healthy, normal weight and age matched individuals were included. Anthropometric parameters, markers of glucose and lipid metabolism, and serum levels of inflammatory and endothelial dysfunction biomarkers were assessed in all subjects. Results: The mean serum 25(OH)D level was significantly lower in the obese group than in controls (33.5 +/- 15.2 vs. 60.1 +/- 23.1 nmol/l; p LT 0.001). In the obese group, sE-selectin (36.4 (32.1-47.2) vs. 32.4 (24.6-35.5) ng/ml, p LT 0.05) and hsCRP (6.0 +/- 3.4 vs. 3.5 1.0 mg/l, p LT 0.05) were significantly higher in individuals with lower than median vitamin D levels (i.e. 31 nmol/l) compared with those with higher vitamin D levels. In multivariable linear regression analysis, hsCRP (beta = 0.43; p LT 0.001) and sE-selectin (beta = 0.30; p = 0.03) were independently and significantly associated with serum 25(OH)D levels in the obese group. Conclusions: Vitamin D levels may be related to increased levels of biomarkers of endothelial dysfunction and inflammation in obese non-diabetic individuals.
T2  - Archives of Medical Science
T1  - Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study
VL  - 13
IS  - 1
SP  - 53
EP  - 60
DO  - 10.5114/aoms.2016.61812
ER  - 

@article{
author = "Ilinčić, Branislava and Stokić, Edita and Stošić, Zoran and Kojić, Nevena Eremic and Katsiki, Niki and Mikhailidis, Dimitri P. and Isenović, Esma R.",
year = "2017",
abstract = "Introduction: Obesity and inadequate vitamin D status are associated with endothelial dysfunction and cardiovascular disease. We evaluated the associations between vitamin D status (i.e. serum levels of 25-hydroxyvitamin D (25(OH)D)), biomarkers of endothelial dysfunction (i.e. serum concentrations of soluble intercellular adhesion molecule 1 (sICAM-1) and soluble E-selectin (sE-selectin)), inflammatory markers (i.e. high-sensitivity C-reactive protein (hsCRP) and fibrinogen) and cardiometabolic risk factors. Material and methods: Fifty obese (body mass index (BMI) GT = 30 kg/m(2)) non-diabetic adults (mean age: 36.2 +/- 5.4 years) without pre-existing cardiovascular abnormalities and 25 clinically healthy, normal weight and age matched individuals were included. Anthropometric parameters, markers of glucose and lipid metabolism, and serum levels of inflammatory and endothelial dysfunction biomarkers were assessed in all subjects. Results: The mean serum 25(OH)D level was significantly lower in the obese group than in controls (33.5 +/- 15.2 vs. 60.1 +/- 23.1 nmol/l; p LT 0.001). In the obese group, sE-selectin (36.4 (32.1-47.2) vs. 32.4 (24.6-35.5) ng/ml, p LT 0.05) and hsCRP (6.0 +/- 3.4 vs. 3.5 1.0 mg/l, p LT 0.05) were significantly higher in individuals with lower than median vitamin D levels (i.e. 31 nmol/l) compared with those with higher vitamin D levels. In multivariable linear regression analysis, hsCRP (beta = 0.43; p LT 0.001) and sE-selectin (beta = 0.30; p = 0.03) were independently and significantly associated with serum 25(OH)D levels in the obese group. Conclusions: Vitamin D levels may be related to increased levels of biomarkers of endothelial dysfunction and inflammation in obese non-diabetic individuals.",
journal = "Archives of Medical Science",
title = "Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study",
volume = "13",
number = "1",
pages = "53-60",
doi = "10.5114/aoms.2016.61812"
}

Ilinčić, B., Stokić, E., Stošić, Z., Kojić, N. E., Katsiki, N., Mikhailidis, D. P.,& Isenović, E. R.. (2017). Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study. in Archives of Medical Science, 13(1), 53-60.
https://doi.org/10.5114/aoms.2016.61812

Ilinčić B, Stokić E, Stošić Z, Kojić NE, Katsiki N, Mikhailidis DP, Isenović ER. Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study. in Archives of Medical Science. 2017;13(1):53-60.
doi:10.5114/aoms.2016.61812 .

Ilinčić, Branislava, Stokić, Edita, Stošić, Zoran, Kojić, Nevena Eremic, Katsiki, Niki, Mikhailidis, Dimitri P., Isenović, Esma R., "Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study" in Archives of Medical Science, 13, no. 1 (2017):53-60,
https://doi.org/10.5114/aoms.2016.61812 . .

TY  - JOUR
AU  - Stokić, Edita
AU  - Kupusinac, Aleksandar
AU  - Tomic-Naglic, Dragana
AU  - Smiljenic, Dragana
AU  - Kovacev-Zavisic, Branka
AU  - Srdić-Galić, Biljana
AU  - Soskić, Sanja S.
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/673
AB  - Vitamin D deficiency and dysfunctional adipose tissue are involved in the development of cardiometabolic disturbances (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We evaluated the relation between vitamin D and adipocytokines derived from adipose tissue. We studied 50 obese individuals who were classified into different subgroups according to medians of observed anthropometric parameters (body mass index, body fat percentage, waist circumference, and trunk fat mass). There was a negative correlation between vitamin D level and leptin and resistin (r = -.61, P LT .01), while a positive association with adiponectin concentrations was found (r = .7, P LT .001). Trend estimation showed that increase in vitamin D level is accompanied by intensive increase in adiponectin concentrations (growth coefficient: 12.13). In conclusion, a positive trend was established between vitamin D and the protective adipocytokine adiponectin. The clinical relevance of this relationship needs to be investigated in larger studies.
T2  - Angiology
T1  - Vitamin D and Dysfunctional Adipose Tissue in Obesity
VL  - 66
IS  - 7
SP  - 613
EP  - 618
DO  - 10.1177/0003319714543512
ER  - 

@article{
author = "Stokić, Edita and Kupusinac, Aleksandar and Tomic-Naglic, Dragana and Smiljenic, Dragana and Kovacev-Zavisic, Branka and Srdić-Galić, Biljana and Soskić, Sanja S. and Isenović, Esma R.",
year = "2015",
abstract = "Vitamin D deficiency and dysfunctional adipose tissue are involved in the development of cardiometabolic disturbances (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We evaluated the relation between vitamin D and adipocytokines derived from adipose tissue. We studied 50 obese individuals who were classified into different subgroups according to medians of observed anthropometric parameters (body mass index, body fat percentage, waist circumference, and trunk fat mass). There was a negative correlation between vitamin D level and leptin and resistin (r = -.61, P LT .01), while a positive association with adiponectin concentrations was found (r = .7, P LT .001). Trend estimation showed that increase in vitamin D level is accompanied by intensive increase in adiponectin concentrations (growth coefficient: 12.13). In conclusion, a positive trend was established between vitamin D and the protective adipocytokine adiponectin. The clinical relevance of this relationship needs to be investigated in larger studies.",
journal = "Angiology",
title = "Vitamin D and Dysfunctional Adipose Tissue in Obesity",
volume = "66",
number = "7",
pages = "613-618",
doi = "10.1177/0003319714543512"
}

Stokić, E., Kupusinac, A., Tomic-Naglic, D., Smiljenic, D., Kovacev-Zavisic, B., Srdić-Galić, B., Soskić, S. S.,& Isenović, E. R.. (2015). Vitamin D and Dysfunctional Adipose Tissue in Obesity. in Angiology, 66(7), 613-618.
https://doi.org/10.1177/0003319714543512

Stokić E, Kupusinac A, Tomic-Naglic D, Smiljenic D, Kovacev-Zavisic B, Srdić-Galić B, Soskić SS, Isenović ER. Vitamin D and Dysfunctional Adipose Tissue in Obesity. in Angiology. 2015;66(7):613-618.
doi:10.1177/0003319714543512 .

Stokić, Edita, Kupusinac, Aleksandar, Tomic-Naglic, Dragana, Smiljenic, Dragana, Kovacev-Zavisic, Branka, Srdić-Galić, Biljana, Soskić, Sanja S., Isenović, Esma R., "Vitamin D and Dysfunctional Adipose Tissue in Obesity" in Angiology, 66, no. 7 (2015):613-618,
https://doi.org/10.1177/0003319714543512 . .

TY  - JOUR
AU  - Stokić, Edita
AU  - Kupusinac, Aleksandar
AU  - Tomic-Naglic, Dragana
AU  - Zavisic, Branka Kovacev
AU  - Mitrovic, Milena
AU  - Smiljenic, Dragana
AU  - Soskić, Sanja S.
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/395
AB  - Vitamin D deficiency is associated with cardiometabolic risk factors (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We studied 50 obese patients (body mass index [BMI]: 43.5 +/- 9.2 kg/m(2)) and 36 normal weight participants (BMI: 22.6 +/- 1.9 kg/m(2)). The prevalence of vitamin D deficiency (25-hydroxyvitamin D, 25(OH)D LT 50 nmol/L) was 88% among obese patients and 31% among nonobese individuals; 25(OH)D levels were lower in the obese group (27.3 +/- 13.7 vs 64.6 +/- 21.3 nmol/L; P LT .001). There was a negative correlation between vitamin D level and anthropometric indicators of obesity: BMI (r = -0.64; P LT .001), waist circumference (r = -0.59; P LT .001), and body fat percentage (r = -0.64; P LT .001) as well as with fasting plasma insulin (r = -0.35; P LT .001) and homeostasis model assessment of insulin resistance (r = -0.35; P LT .001). In conclusion, we observed a higher prevalence of vitamin D deficiency among obese participants and this was associated with a proatherogenic cardiometabolic risk profile.
T2  - Angiology
T1  - Obesity and Vitamin D Deficiency: Trends to Promote a More Proatherogenic Cardiometabolic Risk Profile
VL  - 66
IS  - 3
SP  - 237
EP  - 243
DO  - 10.1177/0003319714528569
ER  - 

@article{
author = "Stokić, Edita and Kupusinac, Aleksandar and Tomic-Naglic, Dragana and Zavisic, Branka Kovacev and Mitrovic, Milena and Smiljenic, Dragana and Soskić, Sanja S. and Isenović, Esma R.",
year = "2015",
abstract = "Vitamin D deficiency is associated with cardiometabolic risk factors (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We studied 50 obese patients (body mass index [BMI]: 43.5 +/- 9.2 kg/m(2)) and 36 normal weight participants (BMI: 22.6 +/- 1.9 kg/m(2)). The prevalence of vitamin D deficiency (25-hydroxyvitamin D, 25(OH)D LT 50 nmol/L) was 88% among obese patients and 31% among nonobese individuals; 25(OH)D levels were lower in the obese group (27.3 +/- 13.7 vs 64.6 +/- 21.3 nmol/L; P LT .001). There was a negative correlation between vitamin D level and anthropometric indicators of obesity: BMI (r = -0.64; P LT .001), waist circumference (r = -0.59; P LT .001), and body fat percentage (r = -0.64; P LT .001) as well as with fasting plasma insulin (r = -0.35; P LT .001) and homeostasis model assessment of insulin resistance (r = -0.35; P LT .001). In conclusion, we observed a higher prevalence of vitamin D deficiency among obese participants and this was associated with a proatherogenic cardiometabolic risk profile.",
journal = "Angiology",
title = "Obesity and Vitamin D Deficiency: Trends to Promote a More Proatherogenic Cardiometabolic Risk Profile",
volume = "66",
number = "3",
pages = "237-243",
doi = "10.1177/0003319714528569"
}

Stokić, E., Kupusinac, A., Tomic-Naglic, D., Zavisic, B. K., Mitrovic, M., Smiljenic, D., Soskić, S. S.,& Isenović, E. R.. (2015). Obesity and Vitamin D Deficiency: Trends to Promote a More Proatherogenic Cardiometabolic Risk Profile. in Angiology, 66(3), 237-243.
https://doi.org/10.1177/0003319714528569

Stokić E, Kupusinac A, Tomic-Naglic D, Zavisic BK, Mitrovic M, Smiljenic D, Soskić SS, Isenović ER. Obesity and Vitamin D Deficiency: Trends to Promote a More Proatherogenic Cardiometabolic Risk Profile. in Angiology. 2015;66(3):237-243.
doi:10.1177/0003319714528569 .

Stokić, Edita, Kupusinac, Aleksandar, Tomic-Naglic, Dragana, Zavisic, Branka Kovacev, Mitrovic, Milena, Smiljenic, Dragana, Soskić, Sanja S., Isenović, Esma R., "Obesity and Vitamin D Deficiency: Trends to Promote a More Proatherogenic Cardiometabolic Risk Profile" in Angiology, 66, no. 3 (2015):237-243,
https://doi.org/10.1177/0003319714528569 . .

TY  - JOUR
AU  - Soskić, Sanja S.
AU  - Stokić, Edita
AU  - Obradović, Milan M.
AU  - Sudar, Emina
AU  - Tanić, Nasta
AU  - Kupusinac, Aleksandar
AU  - Đorđević, Jelena D.
AU  - Isenović, Esma R.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/239
AB  - Aim: The aim of this pilot study was to investigate possible associations of LEP promoter polymorphism LEP G-2548A and obesity-associated metabolic and antropometric parameters in obese population. Materials and methods: Group of 31 patients with hyperalimentary type of obesity (mean age: 39.26 +/- 11.45 years; BMI: 41.51 +/- 9.22 kg/m(2)) and 36 healthy, nonobese, normal weight subjects (mean age: 33.55 +/- 6.46 years; BMI: 22.63 +/- 1.94 kg/m(2)) were studied. Blood samples were collected for DNA isolation, serum leptin and serum lipids measurements. LEP G-2548A genotypes were determined by PCR restriction fragment length polymorphism based analyses. Results: No significant differences in genotype and allele frequencies of the LEP G-2548A polymorphism were detected between obese and normal weight subjects. No association was found between this polymorphism and BMI. Obese subjects had statistically significant increase in serum leptin levels compared with control, while no association between leptin concentration and LEP polymorphism LEP G-2548A was found. There is a statistically significant association of LEP G-2548A genotypes with LDL (p LT 0.05), LDL/HDL ratio (p LT 0.001), apoB (p LT 0.01), body weight (p LT 0.001) and waist circumference (p LT 0.001). Conclusion: Our findings indicate that there is an association between LEP G-2548A polymorphism and metabolic and anthropometric parameters in obese patients in a Serbian population.
T2  - Clinical Lipidology
T1  - Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study
VL  - 9
IS  - 5
SP  - 505
EP  - 513
DO  - 10.2217/CLP.14.42
ER  - 

@article{
author = "Soskić, Sanja S. and Stokić, Edita and Obradović, Milan M. and Sudar, Emina and Tanić, Nasta and Kupusinac, Aleksandar and Đorđević, Jelena D. and Isenović, Esma R.",
year = "2014",
abstract = "Aim: The aim of this pilot study was to investigate possible associations of LEP promoter polymorphism LEP G-2548A and obesity-associated metabolic and antropometric parameters in obese population. Materials and methods: Group of 31 patients with hyperalimentary type of obesity (mean age: 39.26 +/- 11.45 years; BMI: 41.51 +/- 9.22 kg/m(2)) and 36 healthy, nonobese, normal weight subjects (mean age: 33.55 +/- 6.46 years; BMI: 22.63 +/- 1.94 kg/m(2)) were studied. Blood samples were collected for DNA isolation, serum leptin and serum lipids measurements. LEP G-2548A genotypes were determined by PCR restriction fragment length polymorphism based analyses. Results: No significant differences in genotype and allele frequencies of the LEP G-2548A polymorphism were detected between obese and normal weight subjects. No association was found between this polymorphism and BMI. Obese subjects had statistically significant increase in serum leptin levels compared with control, while no association between leptin concentration and LEP polymorphism LEP G-2548A was found. There is a statistically significant association of LEP G-2548A genotypes with LDL (p LT 0.05), LDL/HDL ratio (p LT 0.001), apoB (p LT 0.01), body weight (p LT 0.001) and waist circumference (p LT 0.001). Conclusion: Our findings indicate that there is an association between LEP G-2548A polymorphism and metabolic and anthropometric parameters in obese patients in a Serbian population.",
journal = "Clinical Lipidology",
title = "Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study",
volume = "9",
number = "5",
pages = "505-513",
doi = "10.2217/CLP.14.42"
}

Soskić, S. S., Stokić, E., Obradović, M. M., Sudar, E., Tanić, N., Kupusinac, A., Đorđević, J. D.,& Isenović, E. R.. (2014). Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study. in Clinical Lipidology, 9(5), 505-513.
https://doi.org/10.2217/CLP.14.42

Soskić SS, Stokić E, Obradović MM, Sudar E, Tanić N, Kupusinac A, Đorđević JD, Isenović ER. Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study. in Clinical Lipidology. 2014;9(5):505-513.
doi:10.2217/CLP.14.42 .

Soskić, Sanja S., Stokić, Edita, Obradović, Milan M., Sudar, Emina, Tanić, Nasta, Kupusinac, Aleksandar, Đorđević, Jelena D., Isenović, Esma R., "Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study" in Clinical Lipidology, 9, no. 5 (2014):505-513,
https://doi.org/10.2217/CLP.14.42 . .

TY  - JOUR
AU  - Soskić, Sanja S.
AU  - Stokić, Edita
AU  - Isenović, Esma R.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/6013
AB  - Currently, vitamin D deficiency and obesity are pandemic diseases and they are associated with cardiovascular (CV) disease, metabolic syndrome and type 2 diabetes mellitus (T2DM) and other diseases. Concentrations of 25-hydroxyvitamin D (25(OH) D) (25D) are considered as the best indicator of total body vitamin D stores. An association between reduced circulating 25D concentrations and obesity is well known, but the mechanisms are not totally clear. The role of vitamin D supplementation is still uncertain and prospective interventions will establish its influence, if any, in the treatment of obesity. Vitamin D deficiency is associated with the presence of a cardiometabolic risk profile in the obese. Future trials may establish a role for Vitamin D supplementation in individuals at increased CV risk.
T2  - Current Medical Research and Opinion
T1  - The relationship between vitamin D and obesity
VL  - 30
IS  - 6
SP  - 1197
EP  - 1199
DO  - 10.1185/03007995.2014.900004
ER  - 

@article{
author = "Soskić, Sanja S. and Stokić, Edita and Isenović, Esma R.",
year = "2014",
abstract = "Currently, vitamin D deficiency and obesity are pandemic diseases and they are associated with cardiovascular (CV) disease, metabolic syndrome and type 2 diabetes mellitus (T2DM) and other diseases. Concentrations of 25-hydroxyvitamin D (25(OH) D) (25D) are considered as the best indicator of total body vitamin D stores. An association between reduced circulating 25D concentrations and obesity is well known, but the mechanisms are not totally clear. The role of vitamin D supplementation is still uncertain and prospective interventions will establish its influence, if any, in the treatment of obesity. Vitamin D deficiency is associated with the presence of a cardiometabolic risk profile in the obese. Future trials may establish a role for Vitamin D supplementation in individuals at increased CV risk.",
journal = "Current Medical Research and Opinion",
title = "The relationship between vitamin D and obesity",
volume = "30",
number = "6",
pages = "1197-1199",
doi = "10.1185/03007995.2014.900004"
}

Soskić, S. S., Stokić, E.,& Isenović, E. R.. (2014). The relationship between vitamin D and obesity. in Current Medical Research and Opinion, 30(6), 1197-1199.
https://doi.org/10.1185/03007995.2014.900004

Soskić SS, Stokić E, Isenović ER. The relationship between vitamin D and obesity. in Current Medical Research and Opinion. 2014;30(6):1197-1199.
doi:10.1185/03007995.2014.900004 .

Soskić, Sanja S., Stokić, Edita, Isenović, Esma R., "The relationship between vitamin D and obesity" in Current Medical Research and Opinion, 30, no. 6 (2014):1197-1199,
https://doi.org/10.1185/03007995.2014.900004 . .

TY  - CONF
AU  - Stokić, Edita
AU  - Kupusinac, Aleksandar
AU  - Srdić, Biljana
AU  - Tomic-Naglic, D.
AU  - Isenović, Esma R.
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5740
C3  - Cardiology
T1  - Sagittal Abdominal Diameter (Sad) in Identification Obese Patients At Higher Cardiovascular Risk
VL  - 126
SP  - 169
EP  - 169
UR  - https://hdl.handle.net/21.15107/rcub_vinar_5740
ER  - 

@conference{
author = "Stokić, Edita and Kupusinac, Aleksandar and Srdić, Biljana and Tomic-Naglic, D. and Isenović, Esma R.",
year = "2013",
journal = "Cardiology",
title = "Sagittal Abdominal Diameter (Sad) in Identification Obese Patients At Higher Cardiovascular Risk",
volume = "126",
pages = "169-169",
url = "https://hdl.handle.net/21.15107/rcub_vinar_5740"
}

Stokić, E., Kupusinac, A., Srdić, B., Tomic-Naglic, D.,& Isenović, E. R.. (2013). Sagittal Abdominal Diameter (Sad) in Identification Obese Patients At Higher Cardiovascular Risk. in Cardiology, 126, 169-169.
https://hdl.handle.net/21.15107/rcub_vinar_5740

Stokić E, Kupusinac A, Srdić B, Tomic-Naglic D, Isenović ER. Sagittal Abdominal Diameter (Sad) in Identification Obese Patients At Higher Cardiovascular Risk. in Cardiology. 2013;126:169-169.
https://hdl.handle.net/21.15107/rcub_vinar_5740 .

Stokić, Edita, Kupusinac, Aleksandar, Srdić, Biljana, Tomic-Naglic, D., Isenović, Esma R., "Sagittal Abdominal Diameter (Sad) in Identification Obese Patients At Higher Cardiovascular Risk" in Cardiology, 126 (2013):169-169,
https://hdl.handle.net/21.15107/rcub_vinar_5740 .

TY  - JOUR
AU  - Dobutović, Branislava
AU  - Sudar, Emina
AU  - Soskić, Sanja S.
AU  - Obradović, Milan M.
AU  - Nikolić, Dragana
AU  - Gluvić, Zoran
AU  - Stokić, Edita
AU  - Radak, Đorđe J.
AU  - Isenović, Esma R.
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10323
AB  - Gojaznost se danas smatra bolešću savremenog društva i njena zastupljenost u svetu ima karakter epidemije. Istraživanja usmerena na razumevanje biologije adipocitne ćelije i adipoznog tkiva, značajno doprinose rasvetljavanju mnogih aspekata različitih metaboličkih poremećaja koji prate pojavu gojaznosti tj. prekomerenog prisustva adipoznog tkiva. Gojaznost je posledica dugotrajnog pozitivnog energetskog balansa, neprimerenog stilu života savremenog čoveka. Danas je utemeljena činjenica da je adipozno tkivo endokrini organ u kojem se sintetiše i eksprimira više od 60 različitih faktora - adipokina, sa snažnim uticajem na veliki broj metaboličkih procesa u organizmu. Adipokini mogu imati pro-inflamatorno ili anti-inflamatorno dejstvo. Mnogobrojna istraživanja jasno ukazuju na uzročnu vezu gojaznosti i hronične inflamacije slabog inteziteta, koja vodi razvoju poremećaja vezanih za prisustvo gojaznosti, naročito metaboličkih poremećaja koji znatno umanjuju kvalitet života. Svojom endokrinom funkcijom, adipocitne ćelije reflektuju metabolički status i prenose informaciju na druge organe, tkiva kao i centralni nervni sistem.
AB  - Obesity is a disease of the modern society and considering the number of obese people it has character of the worldwide epidemic. Understanding the biology of adipocytes and the events occurring in adipose tissue contributes to clarification of many aspects of the various metabolic disorders associated with obesity and excessive presence of adipose tissue. Overweight in individuals is the result of a long-term positive energy balance inappropriate to life style of the modern man. Today, it is well accepted that adipose tissue is an endocrine organ in which more than 60 of adipokines are synthesized and are expressed with strong influence on a great number of metabolic processes in organism. Adipokines have pro-inflammatory or anti-inflammatory effects. Increasing evidence indicates that obesity is causally linked to a chronic low-grade inflammatory state, and contributes to the development of obesity-linked disorders, in particular to metabolic dysfunction which significantly reduces the quality of life. Adipocytes, with their endocrine function, reflect metabolic status and transport information into organs, tissues and central nervous system, too.
T2  - Medicinska istraživanja
T1  - Patofiziologija gojaznosti
T1  - Pathophysiology of obesity
VL  - 46
IS  - 1
SP  - 43
EP  - 54
UR  - https://hdl.handle.net/21.15107/rcub_vinar_10323
ER  - 

@article{
author = "Dobutović, Branislava and Sudar, Emina and Soskić, Sanja S. and Obradović, Milan M. and Nikolić, Dragana and Gluvić, Zoran and Stokić, Edita and Radak, Đorđe J. and Isenović, Esma R.",
year = "2012",
abstract = "Gojaznost se danas smatra bolešću savremenog društva i njena zastupljenost u svetu ima karakter epidemije. Istraživanja usmerena na razumevanje biologije adipocitne ćelije i adipoznog tkiva, značajno doprinose rasvetljavanju mnogih aspekata različitih metaboličkih poremećaja koji prate pojavu gojaznosti tj. prekomerenog prisustva adipoznog tkiva. Gojaznost je posledica dugotrajnog pozitivnog energetskog balansa, neprimerenog stilu života savremenog čoveka. Danas je utemeljena činjenica da je adipozno tkivo endokrini organ u kojem se sintetiše i eksprimira više od 60 različitih faktora - adipokina, sa snažnim uticajem na veliki broj metaboličkih procesa u organizmu. Adipokini mogu imati pro-inflamatorno ili anti-inflamatorno dejstvo. Mnogobrojna istraživanja jasno ukazuju na uzročnu vezu gojaznosti i hronične inflamacije slabog inteziteta, koja vodi razvoju poremećaja vezanih za prisustvo gojaznosti, naročito metaboličkih poremećaja koji znatno umanjuju kvalitet života. Svojom endokrinom funkcijom, adipocitne ćelije reflektuju metabolički status i prenose informaciju na druge organe, tkiva kao i centralni nervni sistem., Obesity is a disease of the modern society and considering the number of obese people it has character of the worldwide epidemic. Understanding the biology of adipocytes and the events occurring in adipose tissue contributes to clarification of many aspects of the various metabolic disorders associated with obesity and excessive presence of adipose tissue. Overweight in individuals is the result of a long-term positive energy balance inappropriate to life style of the modern man. Today, it is well accepted that adipose tissue is an endocrine organ in which more than 60 of adipokines are synthesized and are expressed with strong influence on a great number of metabolic processes in organism. Adipokines have pro-inflammatory or anti-inflammatory effects. Increasing evidence indicates that obesity is causally linked to a chronic low-grade inflammatory state, and contributes to the development of obesity-linked disorders, in particular to metabolic dysfunction which significantly reduces the quality of life. Adipocytes, with their endocrine function, reflect metabolic status and transport information into organs, tissues and central nervous system, too.",
journal = "Medicinska istraživanja",
title = "Patofiziologija gojaznosti, Pathophysiology of obesity",
volume = "46",
number = "1",
pages = "43-54",
url = "https://hdl.handle.net/21.15107/rcub_vinar_10323"
}

Dobutović, B., Sudar, E., Soskić, S. S., Obradović, M. M., Nikolić, D., Gluvić, Z., Stokić, E., Radak, Đ. J.,& Isenović, E. R.. (2012). Patofiziologija gojaznosti. in Medicinska istraživanja, 46(1), 43-54.
https://hdl.handle.net/21.15107/rcub_vinar_10323

Dobutović B, Sudar E, Soskić SS, Obradović MM, Nikolić D, Gluvić Z, Stokić E, Radak ĐJ, Isenović ER. Patofiziologija gojaznosti. in Medicinska istraživanja. 2012;46(1):43-54.
https://hdl.handle.net/21.15107/rcub_vinar_10323 .

Dobutović, Branislava, Sudar, Emina, Soskić, Sanja S., Obradović, Milan M., Nikolić, Dragana, Gluvić, Zoran, Stokić, Edita, Radak, Đorđe J., Isenović, Esma R., "Patofiziologija gojaznosti" in Medicinska istraživanja, 46, no. 1 (2012):43-54,
https://hdl.handle.net/21.15107/rcub_vinar_10323 .

TY  - JOUR
AU  - Smiljanić, Katarina
AU  - Zafirović, Sonja
AU  - Obradović, Milan M.
AU  - Gluvić, Zoran
AU  - Stokić, Edita
AU  - Putniković, Biljana
AU  - Isenović, Esma R.
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10324
AB  - Glatke mišićne ćelije krvnih sudova (VSMCs) su od vitalnog značaja, kako za strukturu tako i za funkcionisanje i dinamiku krvnih sudova. Proliferacija i abnormalna akumulacija VSMCs su među ključnim događajima u nastanku raznih vaskularnih oboljenja, uključujući aterosklerozu i hipertenziju. Kardiovaskularne bolesti su vodeći uzrok smrtnosti ljudske populacije u čijoj osnovi u najvećoj meri dominira ateroskleroza kao patološka komponenta. Ateroskleroza jedan je od glavnih uzroka infarkta miokarda, moždanog udara i perifernih vaskularnih bolesti, koji čine približno polovinu svih smrtnih slučajeva u razvijenim zemljama. Ona uključuje orkestrirane procese endotelijalne disfunkcije, inflamacije, proliferacije VSMCs i reorganizaciju ekstracelularnog matriksa. Dediferencijacija i proliferacija VSMCs predstavljaju ključne događaje u nastanku aterosklerotskih lezija, postangioplastične restenoze i odbacivanja kalema pri bajpasu krvnih sudova. Trombin je moćni modulator mnogih procesa kao što su regulisanje tonusa i propustljivosti krvnog suda, migracije i proliferacije VSMCs, privlačenja monocita u aterosklerotske lezije i raznih proinflamatornih markera, a sve ovo, takođe, doprinosi progresiji kardiovaskularnih oboljenja.
AB  - Vascular smooth muscle cells (VSMCs) are vital to the structure, functioning and dynamics of blood vessels. Proliferation and abnormal accumulation of VSMCs are among the key events in the development of various vascular diseases including atherosclerosis and hypertension. Cardiovascular diseases are the leading cause of mortality in human population which is based largely dominated by atherosclerosis as a pathological component. Atherosclerosis is a major cause of myocardial infarction, stroke and peripheral vascular disease, which constitute approximately half of all deaths in developed countries. It involves orchestrated processes of endothelial dysfunction, inflammation, proliferation of VSMCs and extracellular matrix reorganization. Dedifferentiation and proliferation of VSMCs is a key event in the development of atherosclerotic lesions, postangioplastic restenosis and rejection of the bypass graft vessels. Thrombin is a potent modulator of many processes such as regulation of muscle tone and permeability of the blood vessel, migration and proliferation of VSMCs, attracting monocytes into atherosclerotic lesions and a variety of inflammatory markers, and all this also contributes to the progression of cardiovascular disease.
T2  - Medicinska istraživanja
T1  - Uloga trombina u proliferaciji glatkih mišićnih ćelija krvnih sudova (VSMCs) i aterosklerozi
T1  - The role of thrombin in the proliferation of vascular smooth muscle cells (VSMCs) and atherosclerosis
VL  - 46
IS  - 2
SP  - 44
EP  - 53
UR  - https://hdl.handle.net/21.15107/rcub_vinar_10324
ER  - 

@article{
author = "Smiljanić, Katarina and Zafirović, Sonja and Obradović, Milan M. and Gluvić, Zoran and Stokić, Edita and Putniković, Biljana and Isenović, Esma R.",
year = "2012",
abstract = "Glatke mišićne ćelije krvnih sudova (VSMCs) su od vitalnog značaja, kako za strukturu tako i za funkcionisanje i dinamiku krvnih sudova. Proliferacija i abnormalna akumulacija VSMCs su među ključnim događajima u nastanku raznih vaskularnih oboljenja, uključujući aterosklerozu i hipertenziju. Kardiovaskularne bolesti su vodeći uzrok smrtnosti ljudske populacije u čijoj osnovi u najvećoj meri dominira ateroskleroza kao patološka komponenta. Ateroskleroza jedan je od glavnih uzroka infarkta miokarda, moždanog udara i perifernih vaskularnih bolesti, koji čine približno polovinu svih smrtnih slučajeva u razvijenim zemljama. Ona uključuje orkestrirane procese endotelijalne disfunkcije, inflamacije, proliferacije VSMCs i reorganizaciju ekstracelularnog matriksa. Dediferencijacija i proliferacija VSMCs predstavljaju ključne događaje u nastanku aterosklerotskih lezija, postangioplastične restenoze i odbacivanja kalema pri bajpasu krvnih sudova. Trombin je moćni modulator mnogih procesa kao što su regulisanje tonusa i propustljivosti krvnog suda, migracije i proliferacije VSMCs, privlačenja monocita u aterosklerotske lezije i raznih proinflamatornih markera, a sve ovo, takođe, doprinosi progresiji kardiovaskularnih oboljenja., Vascular smooth muscle cells (VSMCs) are vital to the structure, functioning and dynamics of blood vessels. Proliferation and abnormal accumulation of VSMCs are among the key events in the development of various vascular diseases including atherosclerosis and hypertension. Cardiovascular diseases are the leading cause of mortality in human population which is based largely dominated by atherosclerosis as a pathological component. Atherosclerosis is a major cause of myocardial infarction, stroke and peripheral vascular disease, which constitute approximately half of all deaths in developed countries. It involves orchestrated processes of endothelial dysfunction, inflammation, proliferation of VSMCs and extracellular matrix reorganization. Dedifferentiation and proliferation of VSMCs is a key event in the development of atherosclerotic lesions, postangioplastic restenosis and rejection of the bypass graft vessels. Thrombin is a potent modulator of many processes such as regulation of muscle tone and permeability of the blood vessel, migration and proliferation of VSMCs, attracting monocytes into atherosclerotic lesions and a variety of inflammatory markers, and all this also contributes to the progression of cardiovascular disease.",
journal = "Medicinska istraživanja",
title = "Uloga trombina u proliferaciji glatkih mišićnih ćelija krvnih sudova (VSMCs) i aterosklerozi, The role of thrombin in the proliferation of vascular smooth muscle cells (VSMCs) and atherosclerosis",
volume = "46",
number = "2",
pages = "44-53",
url = "https://hdl.handle.net/21.15107/rcub_vinar_10324"
}

Smiljanić, K., Zafirović, S., Obradović, M. M., Gluvić, Z., Stokić, E., Putniković, B.,& Isenović, E. R.. (2012). Uloga trombina u proliferaciji glatkih mišićnih ćelija krvnih sudova (VSMCs) i aterosklerozi. in Medicinska istraživanja, 46(2), 44-53.
https://hdl.handle.net/21.15107/rcub_vinar_10324

Smiljanić K, Zafirović S, Obradović MM, Gluvić Z, Stokić E, Putniković B, Isenović ER. Uloga trombina u proliferaciji glatkih mišićnih ćelija krvnih sudova (VSMCs) i aterosklerozi. in Medicinska istraživanja. 2012;46(2):44-53.
https://hdl.handle.net/21.15107/rcub_vinar_10324 .

Smiljanić, Katarina, Zafirović, Sonja, Obradović, Milan M., Gluvić, Zoran, Stokić, Edita, Putniković, Biljana, Isenović, Esma R., "Uloga trombina u proliferaciji glatkih mišićnih ćelija krvnih sudova (VSMCs) i aterosklerozi" in Medicinska istraživanja, 46, no. 2 (2012):44-53,
https://hdl.handle.net/21.15107/rcub_vinar_10324 .

TY  - JOUR
AU  - Sudar, Emina
AU  - Zafirović, Sonja
AU  - Obradović, Milan M.
AU  - Soskić, Sanja S.
AU  - Jovanović, Aleksandra
AU  - Stokić, Edita
AU  - Gluvić, Zoran
AU  - Isenović, Esma R.
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10322
AB  - Gojaznost se definiše kao prekomerno prisustvo masnog tkiva u organizmu koje može dovesti do mnogih zdravstvenih komplikacija koje pogoršavaju kvalitet života i skraćuju životni vek. Gojaznost je rezultat fizioloških odgovora organizma u situaciji kada je kalorijski unos veći od stvarnih energetskih potreba organizma u dužem vremenskom periodu, bez adekvatnog utroška energije. Prema podacima Svetske zdravstvene organizacije (WHO) gojaznost zauzima peto mesto u paleti vodećih uzroka smrti na globalnom nivou i može se definisati kao hroničan poremećaj metabolizma koji je udružen sa kardiovaskularnim oboljenjima (CVD) kao i sa povećanom stopom morbiditeta i mortaliteta. Danas je prihvaćeno mišljenje da je gojaznost usko povezana sa razvojem rezistencije na insulin (IR). Metaboličke i hormonske promene, koje su posledica pre svega visceralne gojaznosti karakteristične za metabolički sindrom, dovode vremenom do pojave IR u adipoznom tkivu, jetri i mišićnom tkivu. Pretpostavlja se da IR koja se javlja usled gojaznosti predstavlja prvi korak u razvoju CVD. Delimično, IR povećava rizik za nastanak nekih CVD zbog hipertenzije i dislipidemije, kao i promena u adipocitokinima, koje vode inflamaciji krvnih sudova. Osim toga, gojaznost nepovoljno utiče kako na hemodinamiku, tako i na strukturu i funkciju kardiovaskularnog sistema (CVS). Kardiovaskularne komplikacije koje su povezane sa gojaznošću doprinose visokoj stopi morbiditeta i mortaliteta. Usled porasta broja gojaznih osoba, kao i prisustva IR i CVD kod ovih osoba, izučavanje masnog tkiva i njegovog uticaja na razvoj različitih patofizioloških stanja kao što su IR i CVD predstavljaju veoma važno polje biomedicinskih istraživanja, rezultati kojih bi zasigurno omogućili nove terapeutske pristupe u lečenju ovih poremećaja. Takođe, u cilju sprečavanja razvoja gojaznosti, a samim tim i oboljenja koja nastaju kao posledica ovog poremećaja, veoma veliki značaj imaju prevencija i edukacija o mogućim aspektima koje prekomerna akumulacija masnog tkiva može imati na normalno funkcionisanje organizma.
AB  - Obesity is defined as abnormal or excessive fat tissue accumulation that may impair health and well-being and also increases death risk. Obesity occurs as a result of physiological responses of the organism in situations when the caloric intake is greater than energy expenditure/ consumption over an extended period of time, resulting in energy conservation. According to the World Health Organization (WHO) overweight and obesity are the fifth of the leading risk factors for global deaths and they could be defined as a chronic metabolic disorder associated with cardiovascular diseases (CVD) and increased risk of morbidity and mortality. Today, it is accepted that obesity is closely related to insulin resistance (IR). Metabolic and hormonal changes occurring first of all with increased visceral obesity which is a characteristic of metabolic syndrome, lead to IR development in adipose, liver and muscle tissue. It is assumed that IR, which occurs due to obesity, represents the first step in CVD development. Partly, IR increases the risk for CVD development due to the presence of multiple risk factors as hypertension and dyslipidemia, and changes in adipocytokines lead to blood vessel inflammation. Besides that, obesity adversely affects hemodynamic, structure and function of cardiovascular system (CVS). Cardiovascular complications associated with obesity greatly contribute to increased risk of morbidity and mortality. Due to the rising number of obese patients and also presence of IR and CVD in these patients, the study of adipose tissue and its effects on the development of various pathophysiological states as IR and CVD represents a very important area of biomedical research which would lead to new therapeutic approaches in these conditions. Also, in order to prevent obesity development and associated disorders, prevention and education are of great importance.
T2  - Medicinska istraživanja
T1  - Gojaznost, rezistencija na insulin i kardiovaskularna oboljenja
T1  - Obesity, insulin resistance and cardiovascular disease
VL  - 46
IS  - 2
SP  - 54
EP  - 59
UR  - https://hdl.handle.net/21.15107/rcub_vinar_10322
ER  - 

@article{
author = "Sudar, Emina and Zafirović, Sonja and Obradović, Milan M. and Soskić, Sanja S. and Jovanović, Aleksandra and Stokić, Edita and Gluvić, Zoran and Isenović, Esma R.",
year = "2012",
abstract = "Gojaznost se definiše kao prekomerno prisustvo masnog tkiva u organizmu koje može dovesti do mnogih zdravstvenih komplikacija koje pogoršavaju kvalitet života i skraćuju životni vek. Gojaznost je rezultat fizioloških odgovora organizma u situaciji kada je kalorijski unos veći od stvarnih energetskih potreba organizma u dužem vremenskom periodu, bez adekvatnog utroška energije. Prema podacima Svetske zdravstvene organizacije (WHO) gojaznost zauzima peto mesto u paleti vodećih uzroka smrti na globalnom nivou i može se definisati kao hroničan poremećaj metabolizma koji je udružen sa kardiovaskularnim oboljenjima (CVD) kao i sa povećanom stopom morbiditeta i mortaliteta. Danas je prihvaćeno mišljenje da je gojaznost usko povezana sa razvojem rezistencije na insulin (IR). Metaboličke i hormonske promene, koje su posledica pre svega visceralne gojaznosti karakteristične za metabolički sindrom, dovode vremenom do pojave IR u adipoznom tkivu, jetri i mišićnom tkivu. Pretpostavlja se da IR koja se javlja usled gojaznosti predstavlja prvi korak u razvoju CVD. Delimično, IR povećava rizik za nastanak nekih CVD zbog hipertenzije i dislipidemije, kao i promena u adipocitokinima, koje vode inflamaciji krvnih sudova. Osim toga, gojaznost nepovoljno utiče kako na hemodinamiku, tako i na strukturu i funkciju kardiovaskularnog sistema (CVS). Kardiovaskularne komplikacije koje su povezane sa gojaznošću doprinose visokoj stopi morbiditeta i mortaliteta. Usled porasta broja gojaznih osoba, kao i prisustva IR i CVD kod ovih osoba, izučavanje masnog tkiva i njegovog uticaja na razvoj različitih patofizioloških stanja kao što su IR i CVD predstavljaju veoma važno polje biomedicinskih istraživanja, rezultati kojih bi zasigurno omogućili nove terapeutske pristupe u lečenju ovih poremećaja. Takođe, u cilju sprečavanja razvoja gojaznosti, a samim tim i oboljenja koja nastaju kao posledica ovog poremećaja, veoma veliki značaj imaju prevencija i edukacija o mogućim aspektima koje prekomerna akumulacija masnog tkiva može imati na normalno funkcionisanje organizma., Obesity is defined as abnormal or excessive fat tissue accumulation that may impair health and well-being and also increases death risk. Obesity occurs as a result of physiological responses of the organism in situations when the caloric intake is greater than energy expenditure/ consumption over an extended period of time, resulting in energy conservation. According to the World Health Organization (WHO) overweight and obesity are the fifth of the leading risk factors for global deaths and they could be defined as a chronic metabolic disorder associated with cardiovascular diseases (CVD) and increased risk of morbidity and mortality. Today, it is accepted that obesity is closely related to insulin resistance (IR). Metabolic and hormonal changes occurring first of all with increased visceral obesity which is a characteristic of metabolic syndrome, lead to IR development in adipose, liver and muscle tissue. It is assumed that IR, which occurs due to obesity, represents the first step in CVD development. Partly, IR increases the risk for CVD development due to the presence of multiple risk factors as hypertension and dyslipidemia, and changes in adipocytokines lead to blood vessel inflammation. Besides that, obesity adversely affects hemodynamic, structure and function of cardiovascular system (CVS). Cardiovascular complications associated with obesity greatly contribute to increased risk of morbidity and mortality. Due to the rising number of obese patients and also presence of IR and CVD in these patients, the study of adipose tissue and its effects on the development of various pathophysiological states as IR and CVD represents a very important area of biomedical research which would lead to new therapeutic approaches in these conditions. Also, in order to prevent obesity development and associated disorders, prevention and education are of great importance.",
journal = "Medicinska istraživanja",
title = "Gojaznost, rezistencija na insulin i kardiovaskularna oboljenja, Obesity, insulin resistance and cardiovascular disease",
volume = "46",
number = "2",
pages = "54-59",
url = "https://hdl.handle.net/21.15107/rcub_vinar_10322"
}

Sudar, E., Zafirović, S., Obradović, M. M., Soskić, S. S., Jovanović, A., Stokić, E., Gluvić, Z.,& Isenović, E. R.. (2012). Gojaznost, rezistencija na insulin i kardiovaskularna oboljenja. in Medicinska istraživanja, 46(2), 54-59.
https://hdl.handle.net/21.15107/rcub_vinar_10322

Sudar E, Zafirović S, Obradović MM, Soskić SS, Jovanović A, Stokić E, Gluvić Z, Isenović ER. Gojaznost, rezistencija na insulin i kardiovaskularna oboljenja. in Medicinska istraživanja. 2012;46(2):54-59.
https://hdl.handle.net/21.15107/rcub_vinar_10322 .

Sudar, Emina, Zafirović, Sonja, Obradović, Milan M., Soskić, Sanja S., Jovanović, Aleksandra, Stokić, Edita, Gluvić, Zoran, Isenović, Esma R., "Gojaznost, rezistencija na insulin i kardiovaskularna oboljenja" in Medicinska istraživanja, 46, no. 2 (2012):54-59,
https://hdl.handle.net/21.15107/rcub_vinar_10322 .

TY  - JOUR
AU  - Sudar, Emina
AU  - Stokić, Edita
AU  - Nikolić, Dragana
AU  - Dobutović, Branislava
AU  - Soskić, Sanja S.
AU  - Obradović, Milan M.
AU  - Tanasković, Slobodan
AU  - Radak, Đorđe J.
AU  - Isenović, Esma R.
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10326
AB  - Sekretagozi hormona rasta (GHS) su sintetička jedinjenja koja su potentni stimulatori oslobađanja hormona rasta (GH) i deluju preko receptora spregnutog sa guanin nukleotid-vezujućim (G) proteinom, koji se naziva GHS-receptor (GHS-R). Metodom reverzne farmakologije identifikovan je i okarakterisan endogeni ligand za GHS-R tipa 1a (GHS-R1a), koji je nazvan grelin. Grelin je peptidni hormon građen od 28 aminokiselina, u kome je aminokiselina Serin-3 (Ser3) noktanoilovana, odnosno ima modifikaciju u vidu lanca masnih kiselina koja je esencijalna za njegovu aktivnost. Grelin se najviše sintetiše u želucu, a GHS-R su eksprimirani većinom u hipotalamusu i hipofizi. Ishrana je najvažniji faktor koji utiče na regulaciju sekrecije grelina. Koncentracija grelina u cirkulaciji povećana je za vreme gladovanja, a opada nakon uzimanja hrane. Grelin stimuliše oslobađanje GH u mnogo većim količinama nego maksimalne doze GH-oslobađajućeg hormona (GHRH) što ukazuje na drugačiji mehanizam delovanja grelina na nivou hipofize. iRNK za grelin i za GHS-R1a identifikovane su i u srcu i u aorti. Proučavanja efekata grelina, pokazala su njegove povoljne efekte na kardiovaskularni sistem (CVS). S obzirom da grelin stimuliše oslobađanje GH, za koji je ranije pokazano da ima kardioprotektivne efekte, grelin može da ispoljava povoljne efekte na CVS posredovane preko GH, ali i efekte koji su nezavisni od efekata GH. Povoljni efekti grelina na CVS pružaju mogućnost da se grelin koristi u terapiji oboljenja CVS kao što su poremećaji u radu srca, hipertenzija i bolesti ishemije srca.
AB  - Small synthetic molecules called growth hormone (GH) secretagogues (GHS) stimulate the release of GH from the pituitary. They act through the GHS-receptor (GHS-R), a G protein coupled receptor. Recently, by using a method of reverse pharmacology the endogenous ligand for the GHS-R type 1a (GHS-R1a) has been discovered. Ghrelin is a 28 amino acid peptide hormone in which the third amino acid serine (Ser3) is modified by a fatty acid and this modification is essential for ghrelin's activity. Ghrelin is produced mainly in the stomach and GHS-R is mainly expressed in hypothalamus and in the pituitary. The discovery of ghrelin indicates that the release of GH from the pituitary might be regulated not only by hypothalamic GH-releasing hormone (GHRH), but also by ghrelin derived from the stomach. In addition, ghrelin stimulates appetite by acting on the hypothalamic arcuate nucleus, a region known to control food intake. The tissue distribution of ghrelin is widespread, and it is also present in cardiomyocytes. In addition, expression of mRNA encoding both ghrelin and GHSR-1a has been observed in the heart and aortas. Recent evidence indicates that ghrelin feature a variety of cardiovascular activities, including increase of myocardial contractility, vasodilatation, and protection from myocardial infarction. It has been shown that ghrelin may improve cardiac function partly through GH dependent mechanisms but also, some evidence suggests that ghrelin's cardioprotective activity is independent from GH secretion. Thus, ghrelin may be a new therapeutic agent for the treatment of some cardiovascular disturbances and diseases. Further studies are necessary to investigate the potential mechanisms for the effects of ghrelin on cardiovascular system.
T2  - Medicinska istraživanja
T1  - Opšte osobine i efekti grelina na kardiovaskularni sistem
T1  - Ghrelin structure and cardiovascular effects
VL  - 45
IS  - 4
SP  - 15
EP  - 29
UR  - https://hdl.handle.net/21.15107/rcub_vinar_10326
ER  - 

@article{
author = "Sudar, Emina and Stokić, Edita and Nikolić, Dragana and Dobutović, Branislava and Soskić, Sanja S. and Obradović, Milan M. and Tanasković, Slobodan and Radak, Đorđe J. and Isenović, Esma R.",
year = "2011",
abstract = "Sekretagozi hormona rasta (GHS) su sintetička jedinjenja koja su potentni stimulatori oslobađanja hormona rasta (GH) i deluju preko receptora spregnutog sa guanin nukleotid-vezujućim (G) proteinom, koji se naziva GHS-receptor (GHS-R). Metodom reverzne farmakologije identifikovan je i okarakterisan endogeni ligand za GHS-R tipa 1a (GHS-R1a), koji je nazvan grelin. Grelin je peptidni hormon građen od 28 aminokiselina, u kome je aminokiselina Serin-3 (Ser3) noktanoilovana, odnosno ima modifikaciju u vidu lanca masnih kiselina koja je esencijalna za njegovu aktivnost. Grelin se najviše sintetiše u želucu, a GHS-R su eksprimirani većinom u hipotalamusu i hipofizi. Ishrana je najvažniji faktor koji utiče na regulaciju sekrecije grelina. Koncentracija grelina u cirkulaciji povećana je za vreme gladovanja, a opada nakon uzimanja hrane. Grelin stimuliše oslobađanje GH u mnogo većim količinama nego maksimalne doze GH-oslobađajućeg hormona (GHRH) što ukazuje na drugačiji mehanizam delovanja grelina na nivou hipofize. iRNK za grelin i za GHS-R1a identifikovane su i u srcu i u aorti. Proučavanja efekata grelina, pokazala su njegove povoljne efekte na kardiovaskularni sistem (CVS). S obzirom da grelin stimuliše oslobađanje GH, za koji je ranije pokazano da ima kardioprotektivne efekte, grelin može da ispoljava povoljne efekte na CVS posredovane preko GH, ali i efekte koji su nezavisni od efekata GH. Povoljni efekti grelina na CVS pružaju mogućnost da se grelin koristi u terapiji oboljenja CVS kao što su poremećaji u radu srca, hipertenzija i bolesti ishemije srca., Small synthetic molecules called growth hormone (GH) secretagogues (GHS) stimulate the release of GH from the pituitary. They act through the GHS-receptor (GHS-R), a G protein coupled receptor. Recently, by using a method of reverse pharmacology the endogenous ligand for the GHS-R type 1a (GHS-R1a) has been discovered. Ghrelin is a 28 amino acid peptide hormone in which the third amino acid serine (Ser3) is modified by a fatty acid and this modification is essential for ghrelin's activity. Ghrelin is produced mainly in the stomach and GHS-R is mainly expressed in hypothalamus and in the pituitary. The discovery of ghrelin indicates that the release of GH from the pituitary might be regulated not only by hypothalamic GH-releasing hormone (GHRH), but also by ghrelin derived from the stomach. In addition, ghrelin stimulates appetite by acting on the hypothalamic arcuate nucleus, a region known to control food intake. The tissue distribution of ghrelin is widespread, and it is also present in cardiomyocytes. In addition, expression of mRNA encoding both ghrelin and GHSR-1a has been observed in the heart and aortas. Recent evidence indicates that ghrelin feature a variety of cardiovascular activities, including increase of myocardial contractility, vasodilatation, and protection from myocardial infarction. It has been shown that ghrelin may improve cardiac function partly through GH dependent mechanisms but also, some evidence suggests that ghrelin's cardioprotective activity is independent from GH secretion. Thus, ghrelin may be a new therapeutic agent for the treatment of some cardiovascular disturbances and diseases. Further studies are necessary to investigate the potential mechanisms for the effects of ghrelin on cardiovascular system.",
journal = "Medicinska istraživanja",
title = "Opšte osobine i efekti grelina na kardiovaskularni sistem, Ghrelin structure and cardiovascular effects",
volume = "45",
number = "4",
pages = "15-29",
url = "https://hdl.handle.net/21.15107/rcub_vinar_10326"
}

Sudar, E., Stokić, E., Nikolić, D., Dobutović, B., Soskić, S. S., Obradović, M. M., Tanasković, S., Radak, Đ. J.,& Isenović, E. R.. (2011). Opšte osobine i efekti grelina na kardiovaskularni sistem. in Medicinska istraživanja, 45(4), 15-29.
https://hdl.handle.net/21.15107/rcub_vinar_10326

Sudar E, Stokić E, Nikolić D, Dobutović B, Soskić SS, Obradović MM, Tanasković S, Radak ĐJ, Isenović ER. Opšte osobine i efekti grelina na kardiovaskularni sistem. in Medicinska istraživanja. 2011;45(4):15-29.
https://hdl.handle.net/21.15107/rcub_vinar_10326 .

Sudar, Emina, Stokić, Edita, Nikolić, Dragana, Dobutović, Branislava, Soskić, Sanja S., Obradović, Milan M., Tanasković, Slobodan, Radak, Đorđe J., Isenović, Esma R., "Opšte osobine i efekti grelina na kardiovaskularni sistem" in Medicinska istraživanja, 45, no. 4 (2011):15-29,
https://hdl.handle.net/21.15107/rcub_vinar_10326 .

TY  - JOUR
AU  - Soskić, Sanja S.
AU  - Dobutović, Branislava
AU  - Sudar, Emina
AU  - Obradović, Milan M.
AU  - Nikolić, Dragana
AU  - Zarić, Božidarka
AU  - Stojanovic, Srdan D.
AU  - Stokić, Edita
AU  - Mikhailidis, Dimitri P.
AU  - Isenović, Esma R.
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4519
AB  - The peroxisome proliferator-activated receptors (PPARs) represent the family of 3 nuclear receptor isoforms-PPAR alpha, -gamma, and -delta/beta, which are encoded by different genes. As lipid sensors, they are primarily involved in regulation of lipid metabolism and subsequently in inflammation and atherosclerosis. Atherosclerosis considers accumulation of the cells and extracellular matrix in the vessel wall leading to the formation of atherosclerotic plaque, atherothrombosis, and other vascular complications. Besides existence of natural ligands for PPARs, their more potent synthetic ligands are fibrates and thiazolidindiones. Future investigations should now focus on the mechanisms of PPARs activation, which might present new approaches involved in the antiatherosclerotic effects revealed in this review. In addition, in this review we are presenting latest data from recent performed clinical studies which have focus on novel approach to PPARs agonists as potential therapeutic agents in the treatment of complex disease such as atherosclerosis.
T2  - Angiology
T1  - Peroxisome Proliferator-Activated Receptors and Atherosclerosis
VL  - 62
IS  - 7
SP  - 523
EP  - 534
DO  - 10.1177/0003319711401012
ER  - 

@article{
author = "Soskić, Sanja S. and Dobutović, Branislava and Sudar, Emina and Obradović, Milan M. and Nikolić, Dragana and Zarić, Božidarka and Stojanovic, Srdan D. and Stokić, Edita and Mikhailidis, Dimitri P. and Isenović, Esma R.",
year = "2011",
abstract = "The peroxisome proliferator-activated receptors (PPARs) represent the family of 3 nuclear receptor isoforms-PPAR alpha, -gamma, and -delta/beta, which are encoded by different genes. As lipid sensors, they are primarily involved in regulation of lipid metabolism and subsequently in inflammation and atherosclerosis. Atherosclerosis considers accumulation of the cells and extracellular matrix in the vessel wall leading to the formation of atherosclerotic plaque, atherothrombosis, and other vascular complications. Besides existence of natural ligands for PPARs, their more potent synthetic ligands are fibrates and thiazolidindiones. Future investigations should now focus on the mechanisms of PPARs activation, which might present new approaches involved in the antiatherosclerotic effects revealed in this review. In addition, in this review we are presenting latest data from recent performed clinical studies which have focus on novel approach to PPARs agonists as potential therapeutic agents in the treatment of complex disease such as atherosclerosis.",
journal = "Angiology",
title = "Peroxisome Proliferator-Activated Receptors and Atherosclerosis",
volume = "62",
number = "7",
pages = "523-534",
doi = "10.1177/0003319711401012"
}

Soskić, S. S., Dobutović, B., Sudar, E., Obradović, M. M., Nikolić, D., Zarić, B., Stojanovic, S. D., Stokić, E., Mikhailidis, D. P.,& Isenović, E. R.. (2011). Peroxisome Proliferator-Activated Receptors and Atherosclerosis. in Angiology, 62(7), 523-534.
https://doi.org/10.1177/0003319711401012

Soskić SS, Dobutović B, Sudar E, Obradović MM, Nikolić D, Zarić B, Stojanovic SD, Stokić E, Mikhailidis DP, Isenović ER. Peroxisome Proliferator-Activated Receptors and Atherosclerosis. in Angiology. 2011;62(7):523-534.
doi:10.1177/0003319711401012 .

Soskić, Sanja S., Dobutović, Branislava, Sudar, Emina, Obradović, Milan M., Nikolić, Dragana, Zarić, Božidarka, Stojanovic, Srdan D., Stokić, Edita, Mikhailidis, Dimitri P., Isenović, Esma R., "Peroxisome Proliferator-Activated Receptors and Atherosclerosis" in Angiology, 62, no. 7 (2011):523-534,
https://doi.org/10.1177/0003319711401012 . .

TY  - JOUR
AU  - Trpković, Andreja
AU  - Stokić, Edita
AU  - Radak, Đorđe J.
AU  - Gluvić, Zoran
AU  - Haidara, Mohamed A.
AU  - Mikhailidis, Dimitri P.
AU  - Isenović, Esma R.
PY  - 2010
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4208
AB  - The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.
T2  - Current Pharmaceutical Design
T1  - Chronic Hepatitis C, Insulin Resistance and Vascular Disease
VL  - 16
IS  - 34
SP  - 3823
EP  - 3829
DO  - 10.2174/138161210794455067
ER  - 

@article{
author = "Trpković, Andreja and Stokić, Edita and Radak, Đorđe J. and Gluvić, Zoran and Haidara, Mohamed A. and Mikhailidis, Dimitri P. and Isenović, Esma R.",
year = "2010",
abstract = "The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.",
journal = "Current Pharmaceutical Design",
title = "Chronic Hepatitis C, Insulin Resistance and Vascular Disease",
volume = "16",
number = "34",
pages = "3823-3829",
doi = "10.2174/138161210794455067"
}

Trpković, A., Stokić, E., Radak, Đ. J., Gluvić, Z., Haidara, M. A., Mikhailidis, D. P.,& Isenović, E. R.. (2010). Chronic Hepatitis C, Insulin Resistance and Vascular Disease. in Current Pharmaceutical Design, 16(34), 3823-3829.
https://doi.org/10.2174/138161210794455067

Trpković A, Stokić E, Radak ĐJ, Gluvić Z, Haidara MA, Mikhailidis DP, Isenović ER. Chronic Hepatitis C, Insulin Resistance and Vascular Disease. in Current Pharmaceutical Design. 2010;16(34):3823-3829.
doi:10.2174/138161210794455067 .

Trpković, Andreja, Stokić, Edita, Radak, Đorđe J., Gluvić, Zoran, Haidara, Mohamed A., Mikhailidis, Dimitri P., Isenović, Esma R., "Chronic Hepatitis C, Insulin Resistance and Vascular Disease" in Current Pharmaceutical Design, 16, no. 34 (2010):3823-3829,
https://doi.org/10.2174/138161210794455067 . .